Kocitaf - Dolutegravir,Emtricitabine & Tenofovir Alafenamide Tabs

This fixed-dose combination brings together an integrase strand transfer inhibitor (INSTI), Dolutegravir, with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), Emtricitabine and Tenofovir Alafenamide, forming a modern, complete antiretroviral regimen in a single tablet. Dolutegravir works by blocking the integrase enzyme HIV needs to insert its genetic material into human cells, while Emtricitabine and Tenofovir Alafenamide interfere with viral replication at an earlier stage, together providing strong and effective viral suppression. This combined mechanism helps rapidly lower viral load and allows the immune system to recover, often reflected in improved CD4 cell counts over time. Tenofovir Alafenamide, as a newer formulation, delivers the active drug efficiently to cells at a lower dose, which can mean a favorable safety profile for kidney and bone health compared to older tenofovir formulations. Being a single-tablet, once-daily regimen, this combination can make it easier for patients to maintain consistent adherence, which is key to long-term treatment success. Regular monitoring, including blood tests for viral load, CD4 counts, and kidney function, is generally recommended throughout treatment. Many patients using this combination achieve rapid and durable viral suppression with continued, consistent use. As with all antiretroviral therapies, it should be used under the guidance of a healthcare provider as part of a comprehensive, personalized HIV care plan.